MLN 9708 in Induction and Consolidation for Adults With AML >= 60 Years of Age

PHASE1CompletedINTERVENTIONAL
Enrollment

39

Participants

Timeline

Start Date

January 31, 2016

Primary Completion Date

April 30, 2022

Study Completion Date

April 30, 2022

Conditions
Acute Myeloid Leukemia
Interventions
DRUG

MLN9708

Dose of 1.5 mg or 2.3 mg or 3.0 mg taken by mouth on days 2, 5, 9, 12 of each cycle.

DRUG

Cytarabine

Induction: cytarabine 100 mg/m2/day continuous infusion, days 1-7 Consolidation: cytarabine 2000 mg/m2/day, 3 hour infusion, on days 1-5

DRUG

Daunorubicin

Daunorubicin 60 mg/m2, IV bolus, on days 1-3 of induction, only.

Trial Locations (1)

02114

Massachusetts General Hospital, Boston

Sponsors
All Listed Sponsors
collaborator

Millennium Pharmaceuticals, Inc.

INDUSTRY

lead

Massachusetts General Hospital

OTHER